Lantheus Holdings, Inc. operates in the specialized radiopharmaceutical space with products such as PYLARIFY and Neuraceq anchored in oncology and neurology imaging. The company has demonstrated steady revenue growth driven by its core imaging agents but faces notable challenges from patent expirations, evolving reimbursement frameworks, and competitive entries. Recently completed acquisitions expand its product pipeline and commercial footprint, though integration risks remain. Capital allocation emphasizes stock repurchases alongside investments in manufacturing capacity and clinical development. Investors should monitor upcoming FDA decisions on new formulations and patent-litigation developments, which will materially influence near-term performance.